^
    Back
    Association details:
    Biomarker:FOLR1 expression
    Cancer:Peritoneal Cancer
    Drug:Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC)/Fallopian Tube/Primary Peritoneal Cancer….Recurrence Therapy for Platinum-Resistant Disease….Preferred Regimens...Targeted Therapy added: Mirvetuximab soravtansine-gynx (for FRα expressing tumors).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

    Excerpt:
    ...Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay 9....
    Trial ID:
    PICCOLO
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Excerpt:
    ...- Patient's tumor must be positive for FRα expression as defined by a score of PS2+ intensity in >75% of cells...
    Trial ID:
    NCT04606914
    More C2 evidence